October 18, 2018
Retrotope released new data at the National Organization of Rare Diseases’ Rare Diseases & Orphan Products Breakthrough Summit (NORD Summit) regarding the impact of RT001 on disease progression in 2 patients with infantile neuroaxonal dystrophy (INAD). Dr. Mark Midei discusses what makes RT001 unique.
April 2, 2017
In this 18 minute presentation, Dr. Harry J. Saal, Retrotope’s Chairman, explains to a TEDx audience how Retrotope’s technology impacts the membranes that are frequently damaged in many neurological diseases.
JANUARY 25, 2017
A presentation at the Moscow State University by CSO Dr. Misha Shchepinov regarding the mechanism of action of Retrotope's RT001, and its effectiveness in a variety of disease models.
October 12, 2015
A presentation at the University of Pennsylvania by Dr. Harry J. Saal, regarding how Retrotope's RT001 addresses the orphan disease Friedreich's ataxia.
August 22, 2015
Interview of CEO Dr. Bob Molinari by Kyle Bryant (FARA) about the RT001 First in Human clinical trial in Friedreich's ataxia.
JUNE 17, 2015
Presentation by Dr. Charles Cantor at ideacity 2015, Toronto, Canada.
JUNE 6, 2015
Interview w Dr. Bob Molinari, CEO and Dr. Harry J. Saal, Chairman